Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of the current study is to investigate the efficacy, safety and tolerability of
BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to
preferably > 1500 mg metformin in patients with type 2 diabetes mellitus with insufficient
glycaemic control